Clinical TrialMay 18, 2026, 04:57 PM
Wave Life Sciences WVE-006 Trial Shows Positive MZ-Like Phenotype
AI Summary
Wave Life Sciences announced positive updated data from its RestorAATion-2 trial for WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The trial demonstrated WVE-006's ability to achieve an MZ-like phenotype, generating 64% wild-type M-AAT and reducing harmful Z-AAT by 71% in the 200 mg biweekly cohort, with sustained effects for at least three months. The therapy also restored dynamic AAT production and maintained a favorable safety profile, positioning it as a potential new standard of care for both lung and liver manifestations of AATD.
Key Highlights
- WVE-006 achieved MZ-like phenotype, generating 64% wild-type M-AAT and reducing Z-AAT by 71% in 200 mg biweekly cohort.
- Total AAT reached 11.9 µM in 200 mg biweekly cohort and 13.6 µM in 400 mg monthly cohort.
- Editing effects were sustained for at least three months following the last dose.
- Restored dynamic AAT production, with significant increases observed during acute phase responses.
- WVE-006 was generally safe and well tolerated with no liver toxicities or serious adverse events.
- Company expects FDA feedback on potential accelerated approval pathway by mid-2026.
- Data from the 600 mg monthly multidose cohort expected in the second half of 2026.
Price Impact
More from WVE